Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery

NCT05648370 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-12-13

No results posted yet for this study

Summary

A prospective, observational study that assesses the clinical feasibility of ctDNA-based liquid biopsy in patients with oligometastatic NSCLC receiving surgery.

Conditions

Interventions

GENETIC

ctDNA testing and whole exome sequencing

Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Wen-Zhao Zhong, Ph.D · Guangdong Provincial People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2024-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05648370 on ClinicalTrials.gov